カテゴリー： Inkwood Research, 医療/バイオ

過敏性腸症候群治療のアジア太平洋市場予測：2021年-2028年

◆英語タイトル：ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

Inkwood Researchが発行した調査報告書（INK21MC010）◆商品コード：INK21MC010
◆発行会社（リサーチ会社）：Inkwood Research
◆発行日：2021年2月1日
◆ページ数：151
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：アジア太平洋
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single UserUSD1,250 ⇒換算￥182,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算￥219,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算￥292,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Inkwood社の本調査レポートは、アジア太平洋の過敏性腸症候群治療市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別分析、製品別分析、流通チャンネル別分析、作用機序別分析、調剤別分析、地域別分析、競争状況などの情報をお届けいたします。
❖ レポートの概要 ❖

KEY FINDINGSThe Asia Pacific irritable bowel syndrome treatment market is predicted to project a CAGR of 8.92% during the forecast period, 2021-2028. The primary factors contributing to the market growth include the increasing focus of eminent manufacturers on geographical expansion and the developing R&D sector.

MARKET INSIGHTS
India, Japan, China, Vietnam, Australia & New Zealand, Indonesia, Thailand, South Korea, and Rest of Asia Pacific are analyzed for the Asia Pacific irritable bowel syndrome treatment market growth evaluation. According to a 2019 study, in Japan, the prevalence of functional constipation (FC) and irritable bowel syndrome (IBS-C) was 8.76% and 4.97%, respectively. IBS-C resulted in more symptoms than FC, leading to impairment of quality of life. The increasing life expectancy in the country is set to result in an increased geriatric population. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, the aged population in 2019 constituted around 28% of the total population. Such factors are expected to increase market growth.
In Australia, one in five people has experienced the symptoms of IBS at some point in time. These are mucus in stools, alternating diarrhea, constipation, and abdominal pain. There is an increasingly aging population in the country. As per the Australian Institute of Health and Welfare, the aging population graph is expected to grow further. In New Zealand, IBS is a relatively common condition. At the same time, it is difficult to gauge the numbers due to the low turn up of people for diagnosis. The geriatric population of the country constitutes 15% of the total population as per the Statistics New Zealand. Such factors are evaluated to drive market growth in Australia & New Zealand.

COMPETITIVE INSIGHTS
Some of the key players in the market include, Novartis AG, Lannett Company Inc, Takeda, Pharmaceutical Company Ltd, Synthetic Biologics Inc, Sebela Pharmaceuticals Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

❖ レポートの目次 ❖

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1.STUDY OBJECTIVES
1.2.SCOPE OF STUDY
1.3.METHODOLOGY
1.4.ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1.MARKET SIZE & ESTIMATES
2.2.MARKET OVERVIEW
3. MARKET DYNAMICS
3.1.KEY DRIVERS
3.1.1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
3.1.2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
3.1.3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
3.1.4. INCREASING GERIATRIC POPULATION
3.2.KEY RESTRAINTS
3.2.1. HIGH COST OF DRUGS
3.2.2. LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
3.2.3. LIMITED TREATMENT OPTIONS
4. KEY ANALYTICS
4.1.PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2.IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
4.3.OPPORTUNITY MATRIX
4.4.VENDOR LANDSCAPE
4.5.KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1.IBS WITH DIARRHEA
5.2.IBS WITH CONSTIPATION
5.3.MIXED IBS
6. MARKET BY PRODUCT
6.1.RIFAXIMIN
6.2.ELUXADOLINE
6.3.LINACLOTIDE
6.4.LUBIPROSTONE
6.5.OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1.DRUG STORES AND RETAIL PHARMACIES
7.2.HOSPITALS’ PHARMACIES
7.3.ONLINE PHARMACIES
8. MARKET BY MECHANISM OF ACTION
8.1.5HT3 ANTAGONIST
8.2.GUANYLATE CYCLASE RECEPTOR-C AGONIST
8.3.CHLORIDE CHANNEL ACTIVATOR
8.4.OTHER MECHANISM OF ACTIONS
9. MARKET BY DOSAGE
9.1.SOLID
9.2.LIQUID
10. GEOGRAPHICAL ANALYSIS
10.1.ASIA PACIFIC
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. JAPAN
10.1.5.2. CHINA
10.1.5.3. AUSTRALIA & NEW ZEALAND
10.1.5.4. INDIA
10.1.5.5. SOUTH KOREA
10.1.5.6. THAILAND
10.1.5.7. INDONESIA
10.1.5.8. VIETNAM
10.1.5.9. REST OF ASIA PACIFIC
11. COMPETITIVE LANDSCAPE
11.1.KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGER & ACQUISITIONS
11.1.2. PRODUCT LAUNCH & DEVELOPMENTS
11.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
11.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
11.2.COMPANY PROFILE
11.2.1. ABBOTT LABORATORIES
11.2.2. BAUSCH HEALTH COMPANIES INC
11.2.3. ALLERGAN PLC
11.2.4. ARDELYX INC
11.2.5. ASTELLAS PHARMA INC
11.2.6. ASTRAZENECA PLC
11.2.7. GLAXOSMITHKLINE PLC
11.2.8. IRONWOOD PHARMACEUTICALS INC
11.2.9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
11.2.10. LANNETT COMPANY INC
11.2.11. NOVARTIS AG
11.2.12. SEBELA PHARMACEUTICALS INC
11.2.13. SYNTHETIC BIOLOGICS INC
11.2.14. TAKEDA PHARMACEUTICAL COMPANY LTD

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT
TABLE 2: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020
FIGURE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020
FIGURE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020
FIGURE 16: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020
FIGURE 20: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020
FIGURE 25: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)
FIGURE 27: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 28: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 29: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 30: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 31: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 32: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 33: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 34: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 35: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 36: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 過敏性腸症候群治療のアジア太平洋市場予測：2021年-2028年(ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 過敏性腸症候群治療の世界市場予測：2021年-2028年
    INK21MC033 / Inkwood Research / 2021年2月1日 / Inkwood社の本調査レポートは、世界の過敏性腸症候群治療市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別（下痢型IBS、便秘型IBS、混合型IBS）分析、製品別分析、流通チャンネル別分析、作用機序別分析、地域別分析、競争状況などの情報をお届けいたします。 ・調査範囲・手法 ・エグゼクティブサマリー...
  • 腸管理システムのアジア太平洋市場予測：2021年-2028年
    INK21MC002 / Inkwood Research / 2021年1月25日 / Inkwood社の本調査レポートは、アジア太平洋の腸管理システム市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、製品別分析、患者別分析、エンドユーザー別分析、地域別分析、競争状況などの情報をお届けいたします。...
  • ウォルフラム症候群治療の世界市場見通し2022年-2028年
    MMG22MY4334 / Market Monitor Global / 2022年5月 / 当調査レポートは次の情報を含め、世界のウォルフラム症候群治療市場規模と予測を収録しています。・世界のウォルフラム症候群治療市場：売上、2017年-2022年、2023年-2028年 ・世界のウォルフラム症候群治療市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年...
  • ドライアイ症候群治療の世界市場2022-2028：製品種類別、流通チャネル別、地域別
    BZW22JN128 / Bizwit Research & Consulting / 2022年5月27日 / Bizwit Research社は、世界のドライアイ症候群治療市場規模が2021年XX百万ドルに達し、2022年から2028年までにXX％成長すると予想しています。本市場調査資料では、ドライアイ症候群治療の世界市場を広く調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、製品種類別（シクロスポリン、局所コルチコステロイド、人工涙液、涙点プラグ、経口オメガサプリメント）分析、流通チャネル別（病院薬局、アイヘルスクリニック、小売薬局、オンライン薬局）分析、地域別分析、競争分析、調査プロセスなど、以下の構成でまとめました。本市場調査資料では、Novartis AG、Otsuka...
  • マルファン症候群治療の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界のマルファン症候群治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にマルファン症候群治療の世界市場のxxx％を占める「大動脈拡張」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のマルファン症候群治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのマルファン症候群治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのマルファン症候群治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 マルファン症候群治療のグローバル主要メーカーには、Aurobindo...

    • ◆H&Iグローバルリサーチのお客様（例）◆